Sugi Predict

Sugi Predict / Compounds / SCHEMBL15071862

SCHEMBL15071862

SCHEMBL15071862

CC1(C)OB(c2ccc(Cl)cc2Cl)OC1(C)C

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 2/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ TP53 P04637 2/20 0.38
▸ LPL P06858 4/20 0.35
▸ LIPG Q9Y5X9 4/20 0.35
▸ EGFR P00533 3/20 0.35
▸ KDM4E B2RXH2 2/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ JAK2 O60674 1/20 0.34
▸ BTK Q06187 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ LMNA P02545 2/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ USP2 O75604 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ AHR P35869 1/20 0.33
▸ HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14900551 0.85 TP53 (0.38) TSHRCYP3A4TP53LPLLIPG
SCHEMBL18113006 0.83 LPL (0.41) TSHRCYP3A4LPLLIPGEGFR
SCHEMBL13285724 0.83 CYP3A4 (0.35) CYP3A4LPLLIPGEGFRJAK2
SCHEMBL16688104 0.83 LPL (0.46) LPLLIPGEGFR
SCHEMBL31554791 0.83 LPL (0.41) TSHRCYP3A4LPLLIPGEGFR
SCHEMBL462939 0.83 JAK2 (0.36) CYP3A4TP53LPLLIPGEGFR
SCHEMBL16282207 0.81 EGFR (0.34) LPLLIPGEGFRJAK2BTK
SCHEMBL2355702 0.81 LPL (0.40) LPLLIPGEGFRJAK2BTK
SCHEMBL771814 0.81 CYP3A4 (0.47) TSHRCYP3A4TP53LPLLIPG
SCHEMBL10269959 0.81 HSD17B10 (0.42) LPLLIPGJAK2BTKHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303570-A1 KINASE INHIBITORS AND USES THEREOF ABM THERAPEUTICS CORP (US) 2023-09-28 — — US disclosed
US-20230303570-A1 KINASE INHIBITORS AND USES THEREOF ABM THERAPEUTICS CORP (US) 2023-09-28 — — US disclosed
US-20230303570-A1 KINASE INHIBITORS AND USES THEREOF ABM THERAPEUTICS CORP (US) 2023-09-28 — — US disclosed
CN-116710453-A Kinase inhibitors and uses thereof 璧辰医药技术股份有限公司 2023-09-05 — — CN disclosed
EP-4192582-A1 KINASE INHIBITORS AND USES THEREOF ABM Therapeutics Corporation (US) 2023-06-14 — — EP disclosed
WO-2022032071-A1 KINASE INHIBITORS AND USES THEREOF ABM THERAPEUTICS CORPORATION (US) 2022-02-10 — — WO disclosed
WO-2013096642-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 — — WO disclosed
US-20130165472-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 — — US disclosed
US-20130165472-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303570-A1 KINASE INHIBITORS AND USES THEREOF ERBB2, ERBB3, ERBB4 TSHR 3215/4885CYP3A4 2522/4885TP53 447/4885
US-20130165472-A1 HETEROARYLS AND USES THEREOF PIK3R4, VPS4B, PIK3C2A TSHR 3499/4885CYP3A4 133/4885TP53 1948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.